-
September 15, 2022: Ratio Therapeutics Appoints Jacob Hesterman, Ph.D., as Chief Data Officer
BOSTON, September 15, 2022 – Ratio Therapeutics Inc., a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers, today announced the appointment of Jacob Hesterman, Ph.D., as the company’s Chief Data Officer (CDO). […] Read more
-
July 6, 2022: Eckert & Ziegler Becomes Contract Manufacturer for Clinical Development Candidates Based on Lutetium-177 and Actinium-225
Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of […] Read more
-
June 10, 2022: Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers
Company Emerges from Stealth Mode with More Than $20 Million in Seed Financing and Fully Funded Development Alliances with Bayer and Lantheus BOSTON, June 10, 2022 /PRNewswire/ — Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers. Founded by entrepreneurial […] Read more
